According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Published Date: 09 Jun 2023

Italy: Deep, long-lasting responses and sustained survival seen with fixed-duration ibrutinib plus venetoclax are maintained in high-risk patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

4.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

5.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot